The future of pharmaceutical manufacturers includes more digitized data collection

Pharmaceutical manufacturers are turning to digitized data collection and integrated solutions to meet regulations, improve visibility into their operations, and create a more transparent supply chain.

According to a new report from PMMI Business Intelligence, “Pharmaceutical Manufacturing, Trends Shaping The Future”, almost half of pharmaceutical manufacturers surveyed collect at least some data digitally, with a handful of operations at major manufacturers gathering 100% of their data. numerically. Of course, this also indicates that half of the pharmaceutical companies included in the survey do not collect digital data, proving the adage that change is slow for the pharmaceutical industry.



“We have fifteen lines and only three are integrated; we will continue to upgrade until all lines are integrated and collecting data digitally.”

— Production engineer, large OTC manufacturer

DSCSA and Digitization

The Drug Security and Supply Chain Act (DSCSA) has been one of the hottest topics in the pharmaceutical industry in recent years, especially as comprehensive serialization and aggregation requirements will come in in force in 2023.

This is nothing new for pharmaceutical manufacturers, who have been familiar with the regulations for years now. Many have already met DSCSA requirements through onboarding and digitization, with 60% of companies surveyed saying they are already fully compliant with upcoming aggregation requirements. This leaves a notable 27% of companies surveyed that still require changes to meet DSCSA requirements (the remaining 13% do not fall under DSCSA regulations).



For businesses already in compliance, the digitization necessary to meet DSCSA aggregation requirements can be seen as an important starting point to further expand digitization and data collection in a business, or to store and analyze collected data further. effectively.

For companies that have yet to achieve compliance, the DSCSA requirements can be viewed as an opportunity to achieve two goals at once. These operations can benefit immensely from looking beyond the DSCSA into a digitalized future, selecting “future-proof” machines and upgrades that will not only meet immediate regulations, but also open the door to proliferation of digitization and integration between operations. Either way, vendors have a significant opportunity to help pharmaceutical manufacturers proactively plan for improvements and purchase equipment that will enable the continued expansion of digitalization in the future.

“We will be serialization compliant by next year once we upgrade the hardware and software for case packers.”

–Associate Director, Packaging Technology, Large Biopharmaceutical Manufacturer

Cybersecurity plays an important role

Cybersecurity is one of the biggest concerns of all manufacturers, pharmaceutical companies are no exception. In a recent survey, 70% of pharmaceutical companies said that cybersecurity is currently one of their biggest operational concerns. This is a particularly critical issue for the pharmaceutical industry with large amounts of proprietary patient data, some collected remotely.



According to PMMI’s report, says Paula Feldman, Senior Director, PMMI Business Intelligence, “it is essential that industry stakeholders work together to secure large, permanent data repositories shared by manufacturers, as well as to establish communications wirelessly between patients, manufacturers, pharmacies and care. safer suppliers.

Source: PMMI Economic Intelligence, Pharmaceutical manufacturing, trends shaping the future

Download the free report below

Comments are closed.